表紙
市場調査レポート

敗血症:パイプライン分析

Septicaemia - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 321936
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
敗血症:パイプライン分析 Septicaemia - Pipeline Review, H2 2014
出版日: 2014年12月31日 ページ情報: 英文 34 Pages
概要

敗血症は、血液中に大量のバクテリアが存在する感染症で、生命に関わる恐れがあります。症候は悪寒、震え、呼吸困難、血小板数の減少、心ポンプ機能の異常、腹痛などです。素因としては、加齢や免疫系の弱体化が挙げられます。治療は抗生物質や昇圧剤を処置します。

当レポートでは、敗血症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

敗血症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Cubist Pharmaceuticals, Inc.
  • Diomune S.L
  • Humabs BioMed SA
  • Sinovac Biotech Ltd.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 分子タイプ別

薬剤プロファイル

  • Monoclonal Antibody for Staphylococcus Aureus Infections
  • Oncocin Analogues for Septicaemia
  • pneumococcal polysaccharide (23-valent) vaccine
  • Small Molecules for Human Septicaemia
  • Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock
  • Small Molecules to Inhibit DHFR for Septicaemia

最近のパイプライン動向

開発が中止された製品

付録

図表

目次
Product Code: GMDHC5984IDB

Summary

Global Markets Direct's, 'Septicaemia - Pipeline Review, H2 2014', provides an overview of the Septicaemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septicaemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septicaemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Septicaemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Septicaemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Septicaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Septicaemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Septicaemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Septicaemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Septicaemia Overview
  • Therapeutics Development
    • Pipeline Products for Septicaemia - Overview
    • Pipeline Products for Septicaemia - Comparative Analysis
  • Septicaemia - Therapeutics under Development by Companies
  • Septicaemia - Therapeutics under Investigation by Universities/Institutes
  • Septicaemia - Pipeline Products Glance
    • Early Stage Products
  • Septicaemia - Products under Development by Companies
  • Septicaemia - Products under Investigation by Universities/Institutes
  • Septicaemia - Companies Involved in Therapeutics Development
    • Cubist Pharmaceuticals, Inc.
    • Diomune S.L
    • Humabs BioMed SA
    • Sinovac Biotech Ltd.
  • Septicaemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • Monoclonal Antibody for Staphylococcus Aureus Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncocin Analogues for Septicaemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pneumococcal polysaccharide (23-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Human Septicaemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Septicaemia - Recent Pipeline Updates
  • Septicaemia - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Septicaemia, H2 2014
  • Number of Products under Development for Septicaemia - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Septicaemia - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014
  • Septicaemia - Pipeline by Diomune S.L, H2 2014
  • Septicaemia - Pipeline by Humabs BioMed SA, H2 2014
  • Septicaemia - Pipeline by Sinovac Biotech Ltd., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Septicaemia Therapeutics - Recent Pipeline Updates, H2 2014
  • Septicaemia - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Septicaemia, H2 2014
  • Number of Products under Development for Septicaemia - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top